20cm速递｜创新药板块进入盈利兑现提速期，创业板医药ETF国泰（159377）飘红

Group 1 - The core viewpoint is that the innovative drug sector is expected to enter a period of accelerated profitability realization by 2025, with leading companies gradually turning losses into profits. The main drivers are rapid commercialization of products and business development (BD) collaborations [1] - The impressive performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core products supported by medical insurance becoming the foundation for revenue growth, while BD collaborations serve as an important means to enhance performance [1] - The investment logic in the sector is shifting towards a focus on "real profitability and hard innovation" [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovative Medicine Index (399275), which has a daily price fluctuation limit of 20%. This index selects listed companies in the biopharmaceutical, medical device, and healthcare service sectors from the ChiNext market to reflect the overall performance of the medical industry [1]